Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine

[1]  R. Boellaard,et al.  Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients , 2009, Journal of Nuclear Medicine.

[2]  G. V. van Dongen,et al.  p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Johan R de Jong,et al.  Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.

[4]  T. Nayak,et al.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. , 2009, Bioconjugate chemistry.

[5]  Anna M. Wu,et al.  Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.

[6]  P. Lambin,et al.  Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET , 2008, Journal of Nuclear Medicine.

[7]  C. R. Leemans,et al.  Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.

[8]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[9]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[10]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[11]  O. Visser,et al.  Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[13]  M. Zalutsky.  Potential of Immuno–Positron Emission Tomography for Tumor Imaging and Immunotherapy Planning , 2006, Clinical Cancer Research.

[14]  R. Boellaard,et al.  Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients , 2006, Clinical Cancer Research.

[15]  W. Oyen,et al.  PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. , 2004, Cancer biotherapy & radiopharmaceuticals.

[16]  R. Boellaard,et al.  Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R. Boellaard,et al.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  G. V. van Dongen,et al.  The promise of immuno-PET in radioimmunotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  R. Boellaard,et al.  Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. , 2003, Cancer biotherapy & radiopharmaceuticals.